Matthew Ingham
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Treatment of gastrointestinal stromal tumor (GIST) with imatinib and other KIT-targeting drugs, has been effective. However, most patients with advanced GIST eventually develop imatinib-resistance and succumb to disease. We have developed mutation-agnostic, network-based methodologies to systematically elucidate and pharmacologically target Master Regulator (MR) proteins representing critical non-oncogene dependencies of cancer cells. Unsupervised, MR-based clustering of 34 GIST patient tumor samples produced two clusters clearly separating imatinib-resistant vs. sensitive tumors. High-throughput profiling of transcriptional responses by two GIST cell lines to FDA approved and late-stage experimental drugs identified six candidate drugs that reversed the MR activity of imatinib-resistant GIST. Predictions were validated in two imatinib-resistant, patient-derived xenograft (PDX) models. The top prediction, linifanib, induced marked tumor growth inhibition in both PDXs across a wide dose range, while selinexor was also effective compared to imatinib. We confirmed in vivo MR activity reversal by these drugs, but not by ineffective drugs. Statement of Significance We leveraged our network-based platforms, OncoTreat and OncoTarget , to characterize Master Regulators of imatinib-resistance in GIST and identify candidate MR-targeting drugs, an unmet clinical need. Top predicted drugs were successfully validated in cognate PDXs, thus providing a path for translation.
Year:
2025
Purpose: We report results from two clinical trials of the cyclic dinucleotide stimulator of IFN genes (STING) agonist ulevostinag. Patients and Methods: In a phase I study (NCT03010176) with an accelerated titration design/modified toxicity probability interval method, participants with advanced/metastatic solid tumors or lymphomas received intratumoral ulevostinag (±intravenous pembrolizumab). In an expansion phase, participants with head and neck squamous cell carcinoma (HNSCC) or triple-negative breast cancer received the combination. Primary objectives were safety/tolerability and identifying the recommended phase II dose; biomarkers were exploratory. In a randomized phase II study (NCT04220866), participants with untreated metastatic or unresectable, recurrent HNSCC received intravenous pembrolizumab (±ulevostinag 540 µg). The primary objective was antitumor activity. Pembrolizumab 200 mg was administered every 3 weeks in both studies. Results: In the phase I study (NCT03010176; N = 156), the most common adverse event was pyrexia (70%). Plasma ulevostinag concentrations increased dose-dependently. Circulating levels of C-X-C motif chemokine 10, IFNγ, and IL-6 showed elevation at 2 to 4 hours, peak at 6 to 8 hours, and plateau/partial resolution at 24 hours but, beyond the 540 µg dose, did not show a clear dose–effect relationship. Ten participants experienced dose-limiting toxicities; the recommended phase II dose for intratumoral ulevostinag was 540 µg. In the phase II study (NCT04220866), 4 of 8 participants treated with combination therapy and 1 of 10 treated with pembrolizumab monotherapy had a complete or partial response. The most common adverse event was pyrexia ( n = 5). Conclusions: Intratumoral ulevostinag (±pembrolizumab) had manageable toxicity, dose-dependent pharmacokinetics, and evidence of STING activation and target engagement. Combination therapy showed antitumor activity in participants with untreated metastatic or unresectable, recurrent HNSCC.
Year:
2025
Supplementary Figure S1. Study design for Study 1. In Arm 1 (part A), treatment with IT ulevostinag began at 10 μg, with dose escalation proceeding based on safety events to a maximum dose of 3000 μg.
Year:
2025
Purpose: To evaluate sitravatinib, an inhibitor of multiple receptor tyrosine kinases (RTK), for the treatment of well-differentiated/dedifferentiated liposarcoma (WD/DD LPS). Patients and Methods: This multicenter, open-label, Phase II trial enrolled patients with advanced WD/DD LPS who had received at least one prior systemic regimen and had progression within 12 weeks of enrollment. Patients received sitravatinib 150 mg (later amended to 120 mg) orally daily. A Simon two-stage design was used to evaluate for an improvement in the primary endpoint, progression-free rate at 12 weeks (PFR 12 ), from 20% to 40%. Secondary endpoints included antitumor activity and safety. A subset of patients underwent paired biopsies analyzed using reverse-phase protein array. Results: Twenty-nine patients enrolled. Median age was 62 years and 31% had received 3 or more prior lines. Most patients (93%) had DDLPS or mixed WD/DD LPS. Overall, 12 of 29 patients (41%) were alive and progression-free at 12 weeks and the study met the primary endpoint. There were no confirmed responses. Median progression-free survival was 11.7 weeks [95% confidence interval (CI): 5.9–35.9] and median overall survival was 31.7 weeks (95% CI: 18.1–90.1). The most common treatment-related adverse events were diarrhea (59%), hypertension (52%), hoarseness (41%), mucositis (31%), and nausea (31%). Baseline expression of phospho-RTKs was not significantly different between patients with and without clinical benefit from sitravatinib, but the number of samples was small. Conclusions: Sitravatinib provided a PFR 12 of 41% and meaningful disease control in a subset of patients with advanced, progressive WD/DD LPS.
Year:
2025
Violin plots and boxplots displaying the (a) genes detected per cell and (b) stress signature expression per cell and (c) mitochondrial fraction of reads in samples profiled from fresh or frozen tissue in this study and in indicated studies by Jerby et. al. (dijon) and Slyper et al. (green), respectively. The upper and lower edges of the boxplot display the 75th and 25th percentiles respectively. Blue violin plots are from scRNA-seq from fresh tissue, and red violin plots are from snRNA-seq on frozen tissue.
Year:
2024
Purpose: Sarcoma encompasses a diverse group of cancers that are typically resistant to current therapies, including immune checkpoint blockade (ICB), and underlying mechanisms are poorly understood. The contexture of sarcomas limits generation of high-quality data using cutting-edge molecular profiling methods, such as single-cell RNA-sequencing, thus hampering progress in understanding these understudied cancers. Experimental Design: Here, we demonstrate feasibility of producing multimodal single-cell genomics and whole-genome sequencing data from frozen tissues, profiling 75,716 cell transcriptomes of five undifferentiated pleomorphic sarcoma and three intimal sarcoma samples, including paired specimens from two patients treated with ICB. Results: We find that genomic diversity decreases in patients with response to ICB, and, in unbiased analyses, identify cancer cell programs associated with therapy resistance. Although interactions of tumor-infiltrating T lymphocytes within the tumor ecosystem increase in ICB responders, clonal expansion of CD8 + T cells alone was insufficient to predict drug responses. Conclusions: This study provides a framework for studying rare tumors and identifies salient and treatment-associated cancer cell intrinsic and tumor microenvironmental features in sarcomas.
Year:
2024
Year:
2022
Collaborators (18)
Jana Biermann
Associate Research Scientist
Columbia University
Prabhjot Mundi
Assistant Professor
Columbia University Irving Medical Center
Emanuela Romano
PSL Research University
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Shing M Lee
Columbia University
Talia Golan
-
John Hyngstrom
Associate Professor, Surgical Oncology
Rush University Medical Center
Mariano Alvarez
Chief Scientific Officer
KweHealth, LLC
Byoung Chul Cho
PI/Professor
-
Gary K. Schwartz
Case Western Reserve University
Joshua Brody
Icahn School of Medicine at Mount Sinai
Sminu Bose
Columbia University Irving Medical Center
Andrea Califano
Columbia University Irving Medical Center
Kevin Harrington
Head of Division of Radiotherapy and Imaging
Institute of Cancer Research
Benjamin Izar
Assistant Professor
Columbia University Irving Medical Center
Brian Van Tine
Professor of Medicine and Pediatrics
Washington University in St. Louis
Sung-Bae Kim
University of Ulsan College of Medicine
Edwin Choy
Associate Professor
Harvard Medical School
Make your next move.
Prepare your application
Review drafts before you send them.